Keystone Symposia Conference | Antibodies as Drugs

Meeting Program

To view program in "24 hour" time (international) click here.

Friday, March 27
3:00 - 7:30 PM	Registration	Foyer
6:30 - 7:30 PM	Refreshments	Foyer
7:30 - 8:30 PM	Keynote Address (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B,C
	David P. Lane, Experimental Therapeutic Centre, Singapore


Saturday, March 28
7:00 - 8:00 AM	Breakfast	Sea to Sky Ballroom A, Lower Level
8:00 - 11:00 AM	Novel Cancer Drug Scaffolds (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B,C
	Andreas G. Plückthun, University of Zürich, Switzerland Ankyrin Repeat Proteins
	Pim Stemmer, Amunix, Inc., USA Antibody Mimetics
	Gregory L. Verdine, Harvard University, USA Stapled Peptides

	David Baker†, University of Washington, USA Talk Title to be Determined
9:20 - 9:40 AM	Coffee Break	Foyer
11:00 AM- 1:00 PM	Poster Setup	Foyer/Mountain View/Sea to Sky Ballroom A
11:00 AM-	On Own for Lunch
1:00 - 10:00 PM	Poster Viewing	Foyer/Mountain View/Sea to Sky Ballroom A
4:30 - 5:00 PM	Coffee Available	Foyer
5:00 - 7:00 PM	Generating and Engineering Novel Antibody Binding Sites Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B
	George Georgiou, University of Texas at Austin, USA Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli
	James D. Marks, University of California, San Francisco, USA Selecting Internalizing Antibodies for Drug Delivery
	Andrew R. M. Bradbury, Los Alamos National Laboratory, USA Novel Selection and Screening Methods for Antibodies
Following Session is for Targeted Cancer Therapies (X8)
5:00 - 7:00 PM	The Chemistry of Targeted Drug Discovery Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom C


	James E. Bradner, Dana-Farber Cancer Institute, USA Targeting Chromatin: Second-Generation Histone Deacetylase Inhibitors

	Saul H. Rosenberg, Abbott Laboratories, USA Targeting Apoptosis: Bcl-2 Family Protein Inhibitors
	Nathanael Gray, Dana-Farber Cancer Center, USA Talk Title to be Determined

7:00 - 8:00 PM	Social Hour w/ Lite Bites	Foyer/Mountain View/Sea to Sky Ballroom A
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Foyer/Mountain View/Sea to Sky Ballroom A
Sunday, March 29
7:00 - 8:00 AM	Breakfast	Sea to Sky Ballroom A, Lower Level
7:00 - 8:00 AM	Poster Setup	Foyer/Mountain View/Sea to Sky Ballroom A
8:00 - 11:00 AM	Engineering Fc Regions for Optimized ADCC and PK Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B
	Louis M. Weiner, Georgetown University Medical Center, USA Optimizing in vitro and in vivo ADCC for Cancer Therapy
	John R. Desjarlais, Xencor, USA Talk Title to be Determined


	Pablo Umaña, GlycArt Biotechnology AG, Switzerland New Glycoengineered Antibodies with Enhanced Effector Functions
	E. Sally Ward, University of Texas Southwestern Medical Center, USA The Fc Receptor, FcRn and its Role in the Homeostasis and Transport of IgG
Following Session is for Targeted Cancer Therapies (X8)
8:00 - 11:00 AM	Cancer Targets Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom C

	Pierre Sonveaux, University of Louvain (UCL) Medical School, Belgium Lactate-fueled Tumor Cell Respiration: a New Paradigm and a New Target for Therapy


	Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA HSP90 as a Cancer Drug Target
	Craig B. Thompson, Abramson Family Cancer Center and Research Institute, University of Pennsylvania, USA Mitochondrial Targets
	D. Gary Gilliland, Brigham and Women's Hospital, USA Talk Title to be Determined
9:20 - 9:40 AM	Coffee Break	Foyer
11:00 AM- 12:00 PM	Lunch	Foyer/Sea to Sky Ballroom A
12:00 - 2:30 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Foyer/Mountain View/Sea to Sky Ballroom A
2:30 - 4:30 PM	Workshop 1	Sea to Sky Ballroom B
	Short Talks to be Chosen from Abstracts, , USA
4:30 - 5:00 PM	Coffee Available	Foyer
5:00 - 7:00 PM	Immune System Activation to Elicit Therapeutic Responses Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B
	Raphael Clynes, Columbia University, USA Conversion of Passive Antibody Therapy to Active Immunity
	Jacques F. Banchereau, Baylor Institute for Immunology Research, USA Targeting DCs for Anti-Tumor Immunity

	Kavita Dhodapkar, Rockefeller University, USA Antibody-Based Induction of Adaptive Immune Response
Following Session is for Targeted Cancer Therapies (X8)
5:00 - 7:00 PM	Autophagy and Metabolism Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom C
	Matthew Vander Heiden, Harvard University, USA Talk Title to be Determined
	Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA Targeting Energy Sensing
	Chi Van Dang, Johns Hopkins University School of Medicine, USA Therapeutic Implications of the Warburg Effect
7:00 PM-	On Own for Dinner
Monday, March 30
7:00 - 8:00 AM	Breakfast	Sea to Sky Ballroom A, Lower Level
8:00 - 11:00 AM	Antibodies for Treatment of Cancer Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B
	Mark X. Sliwkowski, Genentech, Inc., USA HER2 Targeted Therapies
	Andrew M. Scott, Ludwig Institute for Cancer Research, Australia Targeting a Novel EGFR Epitope
	Kerry Chester, University College London, UK Antibody-Directed Enzyme Prodrug Therapy
	Philip E. Thorpe, University of Texas Southwestern Medical Center, USA Targeting the Vasculature for Tumor Therapy
Following Session is for Targeted Cancer Therapies (X8)
8:00 - 11:00 AM	Novel Target Discovery Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom C
	Alan Ashworth, Institute of Cancer Research, UK DNA Damage Repair Pathway Targets
	William G. Kaelin Jr., Dana Farber Cancer Institute, USA New Cancer Targets Based on Synthetic Lethal Interactions with VHL Tumor Suppressor Gene


	Lynda Chin, Dana Farber Cancer Institute, USA Talk Title to be Determined
	Stuart L. Schreiber†, Harvard University, USA Talk Title to be Determined
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Foyer
11:00 AM- 1:00 PM	Poster Setup	Foyer/Mountain View/Sea to Sky Ballroom A
11:00 AM-	On Own for Lunch
1:00 - 10:00 PM	Poster Viewing	Foyer/Mountain View/Sea to Sky Ballroom A
2:30 - 4:30 PM	Workshop 2: Therapeutic Antibodies in the Neurosciences	Sea to Sky Ballroom B
	Eric V. Shusta, University of Wisconsin, Madison, USA Novel Approaches to Traffic Across the Blood Brain Barrier
	Anne Messer, Wadsworth Center, USA Intrabodies for Neurodegeneration Disorders

	Anthony Williamson, Calmune Corporation, USA Antibodies for Prion Based Diseases
Following Workshop is for Targeted Cancer Therapies (X8)
2:30 - 4:30 PM	Workshop 2: Epigenetic Targeting Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom C
	Peter A. Jones, University of Southern California, USA Methyltransferases



	Alan Colowick, Gloucester Pharmaceuticals, USA Talk Title to be Determined

4:30 - 5:00 PM	Coffee Available	Foyer
5:00 - 7:00 PM	Identifying and Predicting Antibody Efficacy and Toxicity Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B
	Peter D. Senter, Seattle Genetics Inc., USA Antibody Drug Conjugates for Cancer Therapy

	Birgit Schoeberl, Merrimack Pharmaceuticals, USA Predicting Response to RTK Targeted Therapies
	Richard H.J. Begent, University of College London, UK Clinical Trial Design: Lessons from the Tegenero Experience
Following Session is for Targeted Cancer Therapies (X8)
5:00 - 7:00 PM	Target Validation Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom C
	Dean Walton Felsher, Stanford University, USA Validating Cancer Targets in Conditional Transgenic Models
	Scott W. Lowe, Cold Spring Harbor Laboratory, USA Target Validation using siRNA
	Peter J. Houghton, St. Jude Children's Research Hospital, USA Tumor Xenograft Models for Target Validation
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Foyer/Mountain View/Sea to Sky Ballroom A
7:30 - 10:00 PM	Poster Session 3 Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Foyer/Mountain View/Sea to Sky Ballroom A
Tuesday, March 31
7:00 - 8:00 AM	Breakfast	Sea to Sky Ballroom A, Lower Level
8:00 - 11:15 AM	Antibodies in the Treatment of Autoimmunity, Allergy and Infectious Diseases Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B
	Ian A. Wilson, The Scripps Research Institute, USA Structural Basis of Antibody Recognition of Influenza Virus
	Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland Human Monoclonal Antibodies from Memory B cells
	Dennis R. Burton, The Scripps Research Institute, USA Antibodies for HIV Therapy and Vaccine Development
	John Haurum, Symphogen, Denmark Polyclonal Recombinant Antibody for ITP and HDN
	Tariq Ghayur, Abbott Bioresearch Center, USA Dual-Variable-Domain (DVD) - Immunoglobulins: A Novel Class of Dual-Specific Biologics
Following Session is for Targeted Cancer Therapies (X8)
8:00 - 11:00 AM	Targeted Therapy Response Prediction Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom C
	Joe W. Gray, Lawrence Berkeley National Laboratory, USA Predicting Targeted Drug Response

	Barbara L. Weber, GlaxoSmithKline, USA Talk Title to be Determined
	Sanford D. Markowitz, Case Western Reserve University, USA Talk Title to be Determined


	Tak W. Mak, Campbell Family Institute for Breast Cancer Research at PMH, UHN, Canada Talk Title to be Determined
9:20 - 9:40 AM	Coffee Break	Foyer
11:15 AM-	On Own for Lunch
4:30 - 5:00 PM	Coffee Available	Foyer
5:00 - 7:00 PM	Imaging in Cancer Drug Discovery (Joint) Registered attendees for this meeting can view Abstracts for this session starting on 02/27/2009	Sea to Sky Ballroom B,C
	Roger Y. Tsien, University of California, San Diego, USA Optical and MR Imaging of Tumors in vivo
	Karl Dane Wittrup, Massachusetts Institute of Technology, USA Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation
	Anna M. Wu, University of California, Los Angeles, USA Optimizing Antibody PK
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Foyer/Mountain View/Sea to Sky Ballroom A
8:00 - 11:00 PM	Entertainment	Foyer/Mountain View/Sea to Sky Ballroom A
Wednesday, April 1
	Departure
*=Session Chair †=Speaker invited, not yet responded.

Keystone Symposia would like to thank the sponsor of this meeting for their generous support:

We gratefully acknowledge additional support for this conference from:

	Seattle Genetics, Inc.
Symphogen

We gratefully acknowledge the companies that provide Keystone Symposia with additional meeting support, including marketing and advertising...

Click here to view these companies

Despite being theorized more than 100 years ago as the “magic bullets” to treat a range of diseases, it is only within the last 10 years that antibodies have become an important class of therapeutics. This meeting will bring together experts from academia and industry to discuss the current state of antibody therapeutics, their mechanism of action in a range of medical indications, novel approaches to improving discovery, manufacturing, formulation, and pharmacokinetics, methods to predict and increase therapeutic efficacy, as well as novel therapeutic opportunities in cancer, infectious diseases, allergy, inflammatory diseases, and the neurosciences. This meeting will be of interest to academic and industry scientists working in all these fields.

Antibodies as Drugs (X7)